X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Jynneos (live nonreplicating smallpox and monkeypox vaccine) is approved for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
Lead Product(s): Live Nonreplicating Smallpox and Monkeypox Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Jynneos
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
Jynneos (live nonreplicating smallpox and monkeypox vaccine) is approved for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
Lead Product(s): Live Nonreplicating Smallpox and Monkeypox Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Jynneos
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
PXVX0317 (CHIKV VLP) vaccine is comprised of chikungunya virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%. It is being evaluated for the treatment of chikungunya fever.
Lead Product(s): CHIKV VLP
Therapeutic Area: Infections and Infectious Diseases Product Name: PXVX0317
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
JYNNEOS® (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) is approved for the prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox and mpox infection.
Lead Product(s): Live Nonreplicating Smallpox and Monkeypox Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Jynneos
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
Under the agreement, Bavarian will supply its Imvanex (MVA-BN or modified vaccinia ankara ) non-replicating smallpox vaccine to rescEU, a strategic reserve within the European Union.
Lead Product(s): Modified Vaccinia Ankara
Therapeutic Area: Infections and Infectious Diseases Product Name: Imvanex
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: European Union
Deal Size: $11.8 million Upfront Cash: Undisclosed
Deal Type: Agreement September 13, 2023
Details:
ABNCoV2 is being developed as a universal booster to any other type of COVID-19 vaccine and has shown potential to boost neutralizing antibodies against SARS-CoV-2, including variants of concern, to levels associated with a high degree of protection.
Lead Product(s): ABNCoV2
Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2023
Details:
PXVX0317 (CHIKV VLP) vaccine candidate was well tolerated and induced a robust and durable serum neutralizing antibody immune response against the Chikungunya virus up to two years.
Lead Product(s): CHIKV VLP
Therapeutic Area: Infections and Infectious Diseases Product Name: PXVX0317
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2023
Details:
MVA-BN RSV is based on bavarian nordic’s proprietary vaccine platform technology, MVA-BN, and incorporates five distinct RSV antigens to stimulate a broad immune response against both RSV subtypes (A and B).
Lead Product(s): MVA-BN-RSV Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN-RSV
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2023
Details:
ABNCoV2 is being developed as a universal booster to any other type of COVID-19 vaccine and has shown potential to boost neutralizing antibodies against SARS-CoV-2, including variants of concern, to levels associated with a high degree of protection.
Lead Product(s): ABNCoV2
Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
PXVX0317 (CHIKV VLP) vaccine candidate was well tolerated and induced a robust and durable serum neutralizing antibody immune response against the Chikungunya virus up to two years.
Lead Product(s): CHIKV VLP
Therapeutic Area: Infections and Infectious Diseases Product Name: PXVX0317
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
